Shots:
- J&J has reported P-III (ASTRO) trial data assessing Tremfya SC induction (400mg at Wks. 0, 4 & 8) followed by maintenance dose of either Tremfya 100mg (SC, Q8W) or 200mg (SC, Q4W) vs PBO in adults (n=418) with mod. to sev. active UC
- At Wk. 48, trial showed improved clinical remission rates of 36.7% (100mg) & 42.9% (200mg) vs 7.2%, with superior symptomatic remission (47.5% & 53.6% vs 14.4%) & endoscopic improvement (44.6% & 47.1% vs 11.5%); endoscopic remission was 25.9% & 26.4% vs 5%
- Subgroup analyses showed significant benefits across EPs in both biologic & JAK inhibitor-naïve & refractory pts at 48wks.; data was presented at UEG’25
Ref: Johnson & Johnson | Image: Johnson & Johnson | Press Release
Related News:- Johnson & Johnson’s Tremfya (Guselkumab) Receives the US FDA’s Approval for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
